BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36497140)

  • 1. Protein Kinase D1 Signaling in Cancer Stem Cells with Epithelial-Mesenchymal Plasticity.
    Guo Y; Jiang Y; Rose JB; Nagaraju GP; Jaskula-Sztul R; Hjelmeland AB; Beck AW; Chen H; Ren B
    Cells; 2022 Dec; 11(23):. PubMed ID: 36497140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
    Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
    Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.
    Han M; Liu M; Wang Y; Chen X; Xu J; Sun Y; Zhao L; Qu H; Fan Y; Wu C
    PLoS One; 2012; 7(6):e39520. PubMed ID: 22761812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential.
    Salnikov AV; Liu L; Platen M; Gladkich J; Salnikova O; Ryschich E; Mattern J; Moldenhauer G; Werner J; Schemmer P; Büchler MW; Herr I
    PLoS One; 2012; 7(9):e46391. PubMed ID: 23050024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of cancer stem-like cells by the induction of epithelial-mesenchymal transition using lentiviral vector carrying E-cadherin shRNA in HT29 cell line.
    Saltanatpour Z; Johari B; Alizadeh A; Lotfinia M; Majidzadeh-A K; Nikbin B; Kadivar M
    J Cell Physiol; 2019 Dec; 234(12):22935-22946. PubMed ID: 31111504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
    Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
    J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.
    Han M; Wang Y; Liu M; Bi X; Bao J; Zeng N; Zhu Z; Mo Z; Wu C; Chen X
    Cancer Sci; 2012 Jun; 103(6):1058-64. PubMed ID: 22435731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
    Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
    Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
    Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-Mesenchymal Transition and Cancer Stem Cells.
    Tanabe S
    Adv Exp Med Biol; 2022; 1393():1-49. PubMed ID: 36587300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF-β/SMAD3 signaling.
    Zhang Z; Xu Y
    Mol Med; 2022 Jul; 28(1):82. PubMed ID: 35854234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.
    Han M; Liu M; Wang Y; Mo Z; Bi X; Liu Z; Fan Y; Chen X; Wu C
    Mol Cell Biochem; 2012 Apr; 363(1-2):427-36. PubMed ID: 22187223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
    Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
    Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
    PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.